BioWorld

April 17, 2002

Pharmacyclics: New Phase III Sharpens Cancer Drug’s Focus

Pharmacyclics Inc. is planning a new Phase III trial of its cancer cell disrupter, Xcytrin, in the sector of patients for whom the drug seems to do the most good those with lung cancer that has metastasized to the brain. (BioWorld Today) Read More

Bacillus subtilis Pinch Hits For B. anthracis To Make Antibodies From Spore Targets For Vaccine

Hatch Expects Election-Year Debates On Health Care Bills

Syntonix Series B Gets $35.8M For Large-Molecule Delivery

Other News To Note

Correction

Plexxikon Raises $27M Privately For Scaffold Discovery System

Today's news in brief

BioWorld

BioWorld briefs for June 29, 2026.

Illustration for mutations in the DNA leading to brain diseases or neurodegenerative disorders

ENCALS 2026: From genetics to advancing strategies against ALS

BioWorld Science

Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...

Next wave of BCI firms builds on pioneers to tackle challenges

BioWorld

With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...

Boehringer Ingelheim identifies new mGlu3 receptor agonists

BioWorld Science

Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...

GT-02897 exerts efficacy in preclinical multiple myeloma

BioWorld Science

Investigators from the Karl Landsteiner University aimed to evaluate the therapeutic potential of a novel CDK9 inhibitor/degrader, GT-02897, for the potential...